Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.





LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

APA-OTS-Meldungen aus dem Finanzsektor in der "BSN Extended Version"
Wichtige Originaltextaussendungen aus der Branche. Wir ergänzen vollautomatisch Bilder aus dem Fundus von photaq.com und Aktieninformationen aus dem Börse Social Network. Wer eine Korrektur zu den Beiträgen wünscht: mailto:office@boerse-social.com . Wir wiederum übernehmen keinerlei Haftung für Augenerkrankungen aufgrund von geballtem Grossbuchstabeneinsatz der Aussender. Wir meinen: Firmennamen, die länger als drei Buchstaben sind, schreibt man nicht durchgängig in Grossbuchstaben (Versalien).
Magazine aktuell


#gabb aktuell



30.11.2022, 5334 Zeichen

Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities
- Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco
- For people with early Alzheimer's (MCI), HMTM improvement in cognition over pre-treatment baseline now shown to be sustained over 18 months
TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage clinical trials for a potential therapy designed to target the Tau pathology of Alzheimer's. Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. As a hallmark of the disease, it is recognised as a key target for disease modifying treatments.
This approach by TauRx contrasts to many in the field, where the focus has largely been on the role of beta-amyloid. Experts in the field are increasingly looking at alternative therapeutic approaches to find a breakthrough treatment that offers clinically meaningful benefit, ease of administration and low burden of care associated with a reassuring safety profile.
Supporting a path to regulatory submissions, the most recent data from LUCIDITY shows sustained improvement in cognition over 18 months over pre-treatment levels in those participants with MCI due to AD, building on previous data shared in October 2022. This treatment effect was seen only at the 16 mg/day dose of HMTM. Sustained cognitive improvement over baseline has not been seen with any other late-stage treatment for Alzheimer's currently being studied. Coupled with the strong safety profile, convenient oral administration, and lack of need for more than routine clinical monitoring, this positions HMTM as a game-changing prospect for the future treatment of this global unmet need.
On hearing the data and explanations for the path forward from TauRx, Dr George Grossberg, Professor, Director Division of Geriatric Psychiatry Department of Psychiatry & Behavioural Neuroscience, St Louis University School of Medicine, commented, "It is encouraging to see data on a potential disease modifying therapy focusing on the role of Tau in Alzheimer's disease. Being an oral agent with a good safety profile is another advance in the disease-modifying arena for Alzheimer's disease."
TauRx will announce further data on completion of the 24-month study in mid-2023, with additional blood-based biomarker data commissioned to be available early next year. Meanwhile, TauRx is preparing for regulatory submissions primarily in the UK, US, and Canada, with other key territories on their target list, including China, to follow alongside additional studies.
The recent announcement of additional investment of USD119 million through a warrants exercise triggered by the study results allows the company to move forward with regulatory submissions and preparation for market availability.
ABOUT LUCIDITY
LUCIDITY is the only late-stage clinical trial specifically targeting the tau pathology of Alzheimer's. Aggregation of abnormal tau protein is one of the hallmark pathologies.
Additional data analysis is ongoing in relation to the 1-year open label phase of the trial, secondary endpoints including MRI volumetric brain scans, and exploratory endpoints. A summary of the LUCIDITY study protocol has recently been published in The Journal of Prevention of Alzheimer's Disease http://dx.doi.org/10.14283/jpad.2022.63).
https://www.luciditytrial.com
ABOUT TAURx PHARMACEUTICALS LTD
The TauRx group of companies was established in 2002 in Singapore, continuing a partnership with the University of Aberdeen, with primary research facilities and operation based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer's and other neurodegenerative diseases due to protein aggregation pathology.
Alzheimer's dementia is a leading cause of death throughout the world and one of the most important public health issues to be addressed globally. TauRx will contribute to addressing this unmet need with data from LUCIDITY and pursuit of regulatory approvals in line with its overall plans to commercialise HMTM and pursue clinical trials in other related neurodegenerative diseases.
https://www.taurx.com
TAU PATHOLOGY IN ALZHEIMER'S
Through dedicated research programs, it is understood that certain age-related factors lead to misfolding and aggregation of tau proteins, and the subsequent formation of tau tangles in Alzheimer's. These tangles disrupt and damage neuronal function, a process that begins many years before symptoms of dementia are seen. Tau pathology has been proven to correlate with the clinical decline (loss of memory and ability to care for oneself) commonly seen in people with Alzheimer's, establishing it as an important target for treatment. HMTM is a tau aggregation inhibitor, which effectively crosses the blood brain barrier to target the source of this damaging process.
View original content:https://www.prnewswire.co.uk/news-releases/lucidity-phase-3-t opline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therap y-in-late-stage-development-301690475.html
Digital press kit: http://www.ots.at/pressemappe/PR162589/aom

BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S4/23: Christian von Banhans




 

Aktien auf dem Radar:AT&S, Strabag, Polytec Group, Kapsch TrafficCom, Warimpex, RHI Magnesita, Wienerberger, EVN, UBM, Rosgix, DO&CO, Österreichische Post, Telekom Austria, RBI, AMS, Cleen Energy, Lenzing, Marinomed Biotech, OMV, Pierer Mobility, Porr, Rosenbauer, SBO, S Immo, Palfinger, FACC, Agrana, Flughafen Wien, Oberbank AG Stamm, Addiko Bank, Frequentis.


Random Partner

Erste Group
Gegründet 1819 als die „Erste österreichische Spar-Casse“, ging die Erste Group 1997 mit der Strategie, ihr Retailgeschäft in die Wachstumsmärkte Zentral- und Osteuropas (CEE) auszuweiten, an die Wiener Börse. Durch zahlreiche Übernahmen und organisches Wachstum hat sich die Erste Group zu einem der größten Finanzdienstleister im östlichen Teil der EU entwickelt.

>> Besuchen Sie 64 weitere Partner auf boerse-social.com/partner


Mehr aktuelle OTS-Meldungen HIER

Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten


Meistgelesen
>> mehr





PIR-Zeichnungsprodukte
AT0000A2YNS1
AT0000A284P0
AT0000A2ZXL2


Newsflow
>> mehr

Börse Social Club Board
>> mehr
    wikifolio-Trades Austro-Aktien 10-11: RBI(3), S Immo(3), OMV(3), Verbund(2), AT&S(2), Flughafen Wien(1), Lenzing(1), Erste Group(1), UBM(1), DO&CO(1), Wienerberger(1), Rosenbauer(1), voestalpine(1), Mayr-Melnhof(1), Polytec Group(1), Kontron(1), Immofinanz(1), Bawag(1), Kapsch TrafficCom(1)
    BSN MA-Event RWE
    BSN MA-Event Porsche Automobil Holding
    Star der Stunde: Zumtobel 1.69%, Rutsch der Stunde: UBM -2.9%
    wikifolio-Trades Austro-Aktien 9-10: AT&S(2), DO&CO(2), EVN(1), AMS(1)
    Star der Stunde: Strabag 1.32%, Rutsch der Stunde: UBM -1.94%
    wikifolio-Trades Austro-Aktien 8-9: Wienerberger(1), voestalpine(1)
    BSN MA-Event Volkswagen Vz.
    BSN Vola-Event adidas

    Featured Partner Video

    Mr. Irrelevant

    Das Sporttagebuch mit Michael Knöppel - 23. Jänner 2023 E-Mail: sporttagebuch.michael@gmail.com Instagram: @das_sporttagebuch Twitter: @Sporttagebuch_
    Das Sporttagebuch mit Michael Knöppel - 23...

    Books josefchladek.com

    Ismo Höltto, Mikko Savolainen, Aku-Kimmo Ripatti
    Suomea tämäkin
    1970
    K. J. Gummerus

    Dimitra Dede
    Metaphors
    2022
    Void

    Shōji Ueda
    Children the Year Around (植田 正治 童暦 映像の現代3)
    1971
    Chuo-koron-sha

    Regina Anzenberger
    Under the Apple Tree
    2022
    AnzenbergerEdition

    Nik Erik Neubauer
    Ko greš na jug, vedno jokaš dvakrat (You Always Cry Twice When You Go to the South)
    2021
    Self published

    LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development


    30.11.2022, 5334 Zeichen

    Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities
    - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco
    - For people with early Alzheimer's (MCI), HMTM improvement in cognition over pre-treatment baseline now shown to be sustained over 18 months
    TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage clinical trials for a potential therapy designed to target the Tau pathology of Alzheimer's. Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. As a hallmark of the disease, it is recognised as a key target for disease modifying treatments.
    This approach by TauRx contrasts to many in the field, where the focus has largely been on the role of beta-amyloid. Experts in the field are increasingly looking at alternative therapeutic approaches to find a breakthrough treatment that offers clinically meaningful benefit, ease of administration and low burden of care associated with a reassuring safety profile.
    Supporting a path to regulatory submissions, the most recent data from LUCIDITY shows sustained improvement in cognition over 18 months over pre-treatment levels in those participants with MCI due to AD, building on previous data shared in October 2022. This treatment effect was seen only at the 16 mg/day dose of HMTM. Sustained cognitive improvement over baseline has not been seen with any other late-stage treatment for Alzheimer's currently being studied. Coupled with the strong safety profile, convenient oral administration, and lack of need for more than routine clinical monitoring, this positions HMTM as a game-changing prospect for the future treatment of this global unmet need.
    On hearing the data and explanations for the path forward from TauRx, Dr George Grossberg, Professor, Director Division of Geriatric Psychiatry Department of Psychiatry & Behavioural Neuroscience, St Louis University School of Medicine, commented, "It is encouraging to see data on a potential disease modifying therapy focusing on the role of Tau in Alzheimer's disease. Being an oral agent with a good safety profile is another advance in the disease-modifying arena for Alzheimer's disease."
    TauRx will announce further data on completion of the 24-month study in mid-2023, with additional blood-based biomarker data commissioned to be available early next year. Meanwhile, TauRx is preparing for regulatory submissions primarily in the UK, US, and Canada, with other key territories on their target list, including China, to follow alongside additional studies.
    The recent announcement of additional investment of USD119 million through a warrants exercise triggered by the study results allows the company to move forward with regulatory submissions and preparation for market availability.
    ABOUT LUCIDITY
    LUCIDITY is the only late-stage clinical trial specifically targeting the tau pathology of Alzheimer's. Aggregation of abnormal tau protein is one of the hallmark pathologies.
    Additional data analysis is ongoing in relation to the 1-year open label phase of the trial, secondary endpoints including MRI volumetric brain scans, and exploratory endpoints. A summary of the LUCIDITY study protocol has recently been published in The Journal of Prevention of Alzheimer's Disease http://dx.doi.org/10.14283/jpad.2022.63).
    https://www.luciditytrial.com
    ABOUT TAURx PHARMACEUTICALS LTD
    The TauRx group of companies was established in 2002 in Singapore, continuing a partnership with the University of Aberdeen, with primary research facilities and operation based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer's and other neurodegenerative diseases due to protein aggregation pathology.
    Alzheimer's dementia is a leading cause of death throughout the world and one of the most important public health issues to be addressed globally. TauRx will contribute to addressing this unmet need with data from LUCIDITY and pursuit of regulatory approvals in line with its overall plans to commercialise HMTM and pursue clinical trials in other related neurodegenerative diseases.
    https://www.taurx.com
    TAU PATHOLOGY IN ALZHEIMER'S
    Through dedicated research programs, it is understood that certain age-related factors lead to misfolding and aggregation of tau proteins, and the subsequent formation of tau tangles in Alzheimer's. These tangles disrupt and damage neuronal function, a process that begins many years before symptoms of dementia are seen. Tau pathology has been proven to correlate with the clinical decline (loss of memory and ability to care for oneself) commonly seen in people with Alzheimer's, establishing it as an important target for treatment. HMTM is a tau aggregation inhibitor, which effectively crosses the blood brain barrier to target the source of this damaging process.
    View original content:https://www.prnewswire.co.uk/news-releases/lucidity-phase-3-t opline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therap y-in-late-stage-development-301690475.html
    Digital press kit: http://www.ots.at/pressemappe/PR162589/aom

    BSN Podcasts
    Christian Drastil: Wiener Börse Plausch

    Börsepeople im Podcast S4/23: Christian von Banhans




     

    Aktien auf dem Radar:AT&S, Strabag, Polytec Group, Kapsch TrafficCom, Warimpex, RHI Magnesita, Wienerberger, EVN, UBM, Rosgix, DO&CO, Österreichische Post, Telekom Austria, RBI, AMS, Cleen Energy, Lenzing, Marinomed Biotech, OMV, Pierer Mobility, Porr, Rosenbauer, SBO, S Immo, Palfinger, FACC, Agrana, Flughafen Wien, Oberbank AG Stamm, Addiko Bank, Frequentis.


    Random Partner

    Erste Group
    Gegründet 1819 als die „Erste österreichische Spar-Casse“, ging die Erste Group 1997 mit der Strategie, ihr Retailgeschäft in die Wachstumsmärkte Zentral- und Osteuropas (CEE) auszuweiten, an die Wiener Börse. Durch zahlreiche Übernahmen und organisches Wachstum hat sich die Erste Group zu einem der größten Finanzdienstleister im östlichen Teil der EU entwickelt.

    >> Besuchen Sie 64 weitere Partner auf boerse-social.com/partner


    Mehr aktuelle OTS-Meldungen HIER

    Useletter

    Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

    Newsletter abonnieren

    Runplugged

    Infos über neue Financial Literacy Audio Files für die Runplugged App
    (kostenfrei downloaden über http://runplugged.com/spreadit)

    per Newsletter erhalten


    Meistgelesen
    >> mehr





    PIR-Zeichnungsprodukte
    AT0000A2YNS1
    AT0000A284P0
    AT0000A2ZXL2


    Newsflow
    >> mehr

    Börse Social Club Board
    >> mehr
      wikifolio-Trades Austro-Aktien 10-11: RBI(3), S Immo(3), OMV(3), Verbund(2), AT&S(2), Flughafen Wien(1), Lenzing(1), Erste Group(1), UBM(1), DO&CO(1), Wienerberger(1), Rosenbauer(1), voestalpine(1), Mayr-Melnhof(1), Polytec Group(1), Kontron(1), Immofinanz(1), Bawag(1), Kapsch TrafficCom(1)
      BSN MA-Event RWE
      BSN MA-Event Porsche Automobil Holding
      Star der Stunde: Zumtobel 1.69%, Rutsch der Stunde: UBM -2.9%
      wikifolio-Trades Austro-Aktien 9-10: AT&S(2), DO&CO(2), EVN(1), AMS(1)
      Star der Stunde: Strabag 1.32%, Rutsch der Stunde: UBM -1.94%
      wikifolio-Trades Austro-Aktien 8-9: Wienerberger(1), voestalpine(1)
      BSN MA-Event Volkswagen Vz.
      BSN Vola-Event adidas

      Featured Partner Video

      Mr. Irrelevant

      Das Sporttagebuch mit Michael Knöppel - 23. Jänner 2023 E-Mail: sporttagebuch.michael@gmail.com Instagram: @das_sporttagebuch Twitter: @Sporttagebuch_
      Das Sporttagebuch mit Michael Knöppel - 23...

      Books josefchladek.com

      Shōji Ueda
      Children the Year Around (植田 正治 童暦 映像の現代3)
      1971
      Chuo-koron-sha

      Regina Anzenberger
      Under the Apple Tree
      2022
      AnzenbergerEdition

      Ismo Höltto, Mikko Savolainen, Aku-Kimmo Ripatti
      Suomea tämäkin
      1970
      K. J. Gummerus

      Paul Graham
      Empty Heaven
      1995
      Scalo

      Tanja Lažetić
      100 Flowers
      2022
      Galerija Fotografija